Battling Drug-Resistant HIV Strains in Newly Infected Patients
WebMD News Archive
Nov. 16, 1999 (Atlanta) -- Swiss researchers are shedding some light on an
emerging concern: drug-resistant strains of HIV -- the virus that causes AIDS
-- in recently infected patients. Some types of HIV are showing resistance to
protease inhibitors -- among the most effective anti-HIV drugs. The
researchers' findings are published in a recent issue of The Lancet.
Highly active antiretroviral therapy (HAART) -- also called HIV/AIDS drug
"cocktail" therapy -- is credited with lowering the rates of
HIV-related disease and death in developed countries such as the U.S. HAART
includes protease inhibitors as well as the older reverse-transcriptase
inhibitors (for example, zidovudine, or AZT).
Resistance of HIV-1 -- the most common form of HIV in the U.S. and other
developed countries -- to antiretroviral drugs is the main cause of HIV
treatment failure. The primary causes of the development of drug-resistant HIV
strains include 1) insufficient treatment to suppress the infection and 2)
patient failure to follow the treatment regimen as directed.
Previous studies had calculated the rate of HIV resistance to zidovudine at
5-15%, but no previous studies had been done to calculate the rate of
resistance to protease inhibitors.
"We analyzed 82 patients with primary HIV-1 in the Geneva area, from
January 1996 to July 1998, and we found 10% of patients [had] mutations
associated with resistance to reverse-transcriptase inhibitor [RTI]
therapy," researcher Sabine Yerly, MSc, tells WebMD. "We thought we'd
find some [resistance,] but we didn't expect to find such a high prevalence of
transmission of resistance -- 10% is a very high percentage." Yerly is a
research associate in the laboratory of senior researcher Luc Perrin, MD, at
the Geneva University Hospital.
"What is also alarming for us is [that] we found 4% of patients with a
resistance to protease inhibitors," says Yerly. "Protease inhibitors in
Switzerland [became] available in 1995. These patients were infected between
1996 and 1998, and it means that in 2 years we [have seen] this resistance
"I don't think this is terribly surprising; it is too bad, but it is
something I think everybody anticipated might happen," Charles Carpenter,
MD, tells WebMD. "I would guess that the likelihood of resistance is very
similar in the big cities on the East Coast [of the U.S.] as it is in Geneva.
Perrin is a first-rate investigator, and his lab is very good; I think the data
are solid." Carpenter, a professor of medicine at Brown University,
reviewed the study for WebMD.